Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antimetabolites"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 7516
Tytuł:
Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study.
Autorzy:
Guo Z; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Guo D; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Kong D; Department of Hematology, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Bian S; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, People's Republic of China.
Lin L; Department of Hematology, Yantai Yuhuangding Hospital, Qingdao University Medical College, Yantai, People's Republic of China.
Fan S; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Li Q; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Zhao Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Jiang Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Yan J; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Wang Z; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Sun L; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Li Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2219930.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Azacitidine*/adverse effects
Histone Deacetylase Inhibitors*/adverse effects
Leukemia, Myeloid, Acute*/metabolism
Antimetabolites, Antineoplastic*/adverse effects
Adult ; Humans ; Cytarabine/therapeutic use ; Decitabine/adverse effects ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial.
Autorzy:
Dong, Yawen (AUTHOR)
Santol, Jonas (AUTHOR)
Gruenberger, Birgit (AUTHOR)
Lenauer, Alfred (AUTHOR)
Laengle, Friedrich (AUTHOR)
Thaler, Josef (AUTHOR)
Piringer, Gudrun (AUTHOR)
Eisterer, Wolfgang (AUTHOR)
Djanani, Angela (AUTHOR)
Stift, Judith (AUTHOR)
Gruenberger, Thomas (AUTHOR)
Pokaż więcej
Źródło:
Cancers. Mar2024, Vol. 16 Issue 5, p857. 14p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Intraocular Metastasis of Large T-cell Lymphoma Transformed from Mycosis Fungoides.
Autorzy:
Chen D; Department of Ophthalmology, New York University School of Medicine, New York University Langone Health, New York, New York, USA.
Modi Y; Department of Ophthalmology, New York University School of Medicine, New York University Langone Health, New York, New York, USA.
Goduni L; Department of Ophthalmology, New York University School of Medicine, New York University Langone Health, New York, New York, USA.
Chong J; Department of Ophthalmology, New York University School of Medicine, New York University Langone Health, New York, New York, USA.
Tsui E; Jules Stein Eye Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA.
Breazzano MP; Department of Ophthalmology, New York University School of Medicine, New York University Langone Health, New York, New York, USA.; Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, New York, USA.
Dedania V; Department of Ophthalmology, New York University School of Medicine, New York University Langone Health, New York, New York, USA.
Marr B; Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, New York, USA.
Sarraf D; Jules Stein Eye Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA.
Pokaż więcej
Źródło:
Ocular immunology and inflammation [Ocul Immunol Inflamm] 2023 Apr; Vol. 31 (3), pp. 585-588. Date of Electronic Publication: 2022 Feb 24.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Intraocular Lymphoma*/drug therapy
Intraocular Lymphoma*/secondary
Intraocular Lymphoma*/surgery
Mycosis Fungoides*/pathology
Skin Neoplasms*/pathology
Methotrexate*/administration & dosage
Methotrexate*/therapeutic use
Antimetabolites, Antineoplastic*/administration & dosage
Antimetabolites, Antineoplastic*/therapeutic use
Humans ; Male ; Middle Aged ; Vitrectomy ; Intravitreal Injections ; Psoriasis/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis.
Autorzy:
Wang Y; School of Mathematics and Physics, University of Science and Technology Beijing, Beijing 100083, China.
Chen X; School of Mathematics and Physics, University of Science and Technology Beijing, Beijing 100083, China.
Tang N; School of Mathematics and Physics, University of Science and Technology Beijing, Beijing 100083, China.
Guo M; School of Mathematics and Physics, University of Science and Technology Beijing, Beijing 100083, China.
Ai D; School of Mathematics and Physics, University of Science and Technology Beijing, Beijing 100083, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Apr 08; Vol. 25 (7). Date of Electronic Publication: 2024 Apr 08.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/drug therapy
Deep Learning*
Kidney Neoplasms*/drug therapy
Humans ; Endothelial Cells ; Algorithms ; Single-Cell Analysis ; Antimetabolites ; DNA Modification Methylases ; Drug Discovery ; DNA ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.
Autorzy:
Malekkou A; Biochemical Genetics Department, The Cyprus Institute of Neurology and Genetics, P. O. Box 23462, 1683, Nicosia, Cyprus.
Tomazou M; Bioinformatics Department, The Cyprus Institute of Neurology and Genetics, P. O. Box 23462, 1683, Nicosia, Cyprus.
Mavrikiou G; Biochemical Genetics Department, The Cyprus Institute of Neurology and Genetics, P. O. Box 23462, 1683, Nicosia, Cyprus.
Dionysiou M; Biochemical Genetics Department, The Cyprus Institute of Neurology and Genetics, P. O. Box 23462, 1683, Nicosia, Cyprus.
Georgiou T; Biochemical Genetics Department, The Cyprus Institute of Neurology and Genetics, P. O. Box 23462, 1683, Nicosia, Cyprus.
Papaevripidou I; Cytogenetics and Genomics Department, The Cyprus Institute of Neurology and Genetics, P. O. Box 23462, 1683, Nicosia, Cyprus.
Alexandrou A; Cytogenetics and Genomics Department, The Cyprus Institute of Neurology and Genetics, P. O. Box 23462, 1683, Nicosia, Cyprus.
Sismani C; Cytogenetics and Genomics Department, The Cyprus Institute of Neurology and Genetics, P. O. Box 23462, 1683, Nicosia, Cyprus.
Drousiotou A; Biochemical Genetics Department, The Cyprus Institute of Neurology and Genetics, P. O. Box 23462, 1683, Nicosia, Cyprus.
Grafakou O; Department of Pediatrics, Inborn Errors of Metabolism Clinic, Archbishop Makarios III Hospital, Korytsas 6, 2012, Nicosia, Cyprus.
Petrou PP; Biochemical Genetics Department, The Cyprus Institute of Neurology and Genetics, P. O. Box 23462, 1683, Nicosia, Cyprus. .
Pokaż więcej
Źródło:
BMC medical genomics [BMC Med Genomics] 2024 Mar 25; Vol. 17 (1), pp. 78. Date of Electronic Publication: 2024 Mar 25.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Dihydropyrimidine Dehydrogenase Deficiency*/genetics
Dihydropyrimidine Dehydrogenase Deficiency*/complications
Dihydropyrimidine Dehydrogenase Deficiency*/drug therapy
Infant ; Humans ; Male ; Dihydrouracil Dehydrogenase (NADP)/genetics ; Dihydrouracil Dehydrogenase (NADP)/metabolism ; Antimetabolites, Antineoplastic/adverse effects ; Fluorouracil/adverse effects ; Genetic Testing
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study.
Autorzy:
De Metz C; Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
Hennart B; Toxicology Unit, Biology and Pathology Centre, Lille University Medical Centre, Lille, France.
Aymes E; Department of Biostatistics, Centre Oscar Lambret, Lille, France.
Cren PY; Department of Medical Oncology, Centre Oscar Lambret, Lille, France.; Department of Biostatistics, Centre Oscar Lambret, Lille, France.
Martignène N; Department of Biostatistics, Centre Oscar Lambret, Lille, France.
Penel N; Department of Medical Oncology, Centre Oscar Lambret, Lille, France.; Univ. Lille, CHU Lille, ULR 2694 - Metrics: Evaluation des technologies de santé et des pratiques médicales, Lille, France.
Barthoulot M; Department of Biostatistics, Centre Oscar Lambret, Lille, France.
Carnot A; Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Mar; Vol. 13 (6), pp. e7066.
Typ publikacji:
Journal Article
MeSH Terms:
Dihydrouracil Dehydrogenase (NADP)*/genetics
Dihydropyrimidine Dehydrogenase Deficiency*/diagnosis
Dihydropyrimidine Dehydrogenase Deficiency*/genetics
Dihydropyrimidine Dehydrogenase Deficiency*/complications
Adult ; Humans ; Antimetabolites, Antineoplastic/therapeutic use ; Retrospective Studies ; Capecitabine ; Genotype ; Fluorouracil
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.
Autorzy:
Kozai H; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Ogino H; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Mitsuhashi A; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Nguyen NT; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Tsukazaki Y; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Yabuki Y; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Ozaki R; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Yoneda H; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Sato S; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Hanibuchi M; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.; Department of Community Medicine for Respirology, Hematology, and Metabolism, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Shinohara T; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.; Department of Community Medicine for Respirology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Nokihara H; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.; Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Nishioka Y; Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (5), pp. 369-378. Date of Electronic Publication: 2023 Dec 26.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Humans ; Animals ; Mice ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; CD8-Positive T-Lymphocytes ; Platinum ; Immunogenic Cell Death ; Pemetrexed ; Antimetabolites ; Cell Line, Tumor ; Taxoids ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use ; Adenosine Triphosphate ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer.
Autorzy:
Nie, Jing (AUTHOR)
Wu, Huina (AUTHOR)
Wu, Qian (AUTHOR)
Liu, Lihui (AUTHOR)
Tang, Ke (AUTHOR)
Wang, Shuo (AUTHOR)
Wu, Jiyong (AUTHOR)
Pokaż więcej
Źródło:
Cost Effectiveness & Resource Allocation. 1/24/2024, Vol. 22 Issue 1, p1-9. 9p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Testing Adaptive Therapy Protocols Using Gemcitabine and Capecitabine in a Preclinical Model of Endocrine-Resistant Breast Cancer.
Autorzy:
Seyedi, Sareh (AUTHOR)
Teo, Ruthanne (AUTHOR)
Foster, Luke (AUTHOR)
Saha, Daniel (AUTHOR)
Mina, Lida (AUTHOR)
Northfelt, Donald (AUTHOR)
Anderson, Karen S. (AUTHOR)
Shibata, Darryl (AUTHOR)
Gatenby, Robert (AUTHOR)
Cisneros, Luis H. (AUTHOR)
Troan, Brigid (AUTHOR)
Anderson, Alexander R. A. (AUTHOR)
Maley, Carlo C. (AUTHOR)
Pokaż więcej
Źródło:
Cancers. Jan2024, Vol. 16 Issue 2, p257. 25p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Preoperative Intensified Chemoradiation with Intensity-Modulated Radiotherapy and Simultaneous Integrated Boost Combined with Capecitabine in Locally Advanced Rectal Cancer: Long-Term Outcomes of a Real-Life Multicenter Study.
Autorzy:
Lupattelli, Marco (AUTHOR)
Palazzari, Elisa (AUTHOR)
Polesel, Jerry (AUTHOR)
Chiloiro, Giuditta (AUTHOR)
Angelicone, Ilaria (AUTHOR)
Panni, Valeria (AUTHOR)
Caravatta, Luciana (AUTHOR)
Di Biase, Saide (AUTHOR)
Macchia, Gabriella (AUTHOR)
Niespolo, Rita Marina (AUTHOR)
Franco, Pierfrancesco (AUTHOR)
Epifani, Valeria (AUTHOR)
Meldolesi, Elisa (AUTHOR)
de Giacomo, Flavia (AUTHOR)
Lucarelli, Marco (AUTHOR)
Montesi, Giampaolo (AUTHOR)
Mantello, Giovanna (AUTHOR)
Innocente, Roberto (AUTHOR)
Osti, Mattia Falchetto (AUTHOR)
Gambacorta, Maria Antonietta (AUTHOR)
Pokaż więcej
Źródło:
Cancers. Dec2023, Vol. 15 Issue 23, p5702. 18p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis.
Autorzy:
Khanam R; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Shahzad M; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Chaudhary SG; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Ali F; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Shah Z; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Pachika PS; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Ahmed Z; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Chattaraj A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Masood A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Bansal R; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Balusu R; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Shune L; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Anwar F; Division of Hematology/Oncology, Cleveland Clinic, Cleveland, OH, USA.
Hematti P; Division of Hematology/Oncology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
McGuirk JP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Yacoub A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Mushtaq MU; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Nov; Vol. 63 (11), pp. 2671-2678. Date of Electronic Publication: 2022 Jun 10.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic*/therapeutic use
Myelodysplastic Syndromes*
Humans ; Retrospective Studies ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Atherosclerosis Vindicated: A Case of Chest Pain Due to Capecitabine-Induced Coronary Artery Spasm.
Autorzy:
Thomesen K; Internal Medicine Residency Program, National Capital Consortium, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Kisling A; Department of Cardiology, National Capital Consortium, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Conte L; Department of Cardiology, National Capital Consortium, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Park D; Department of Hematology and Oncology, National Capital Consortium, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Gallagher R; Department of Cardiology, National Capital Consortium, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Pokaż więcej
Źródło:
The American journal of case reports [Am J Case Rep] 2024 Jan 13; Vol. 25, pp. e941759. Date of Electronic Publication: 2024 Jan 13.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Coronary Vasospasm*/chemically induced
Coronary Vasospasm*/diagnosis
Coronary Vasospasm*/drug therapy
Atherosclerosis*
Male ; Humans ; Middle Aged ; Capecitabine/adverse effects ; Antimetabolites, Antineoplastic/adverse effects ; Chest Pain/chemically induced ; Electrocardiography
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing.
Autorzy:
Turner AJ; RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA.
Haidar CE; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Yang W; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Boone EC; Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
Offer SM; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Empey PE; Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
Haddad A; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
Tahir S; Medical College of Wisconsin, School of Pharmacy, Milwaukee, Wisconsin, USA.
Scharer G; RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA.
Broeckel U; RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA.
Gaedigk A; Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.; School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2024 Jan; Vol. 17 (1), pp. e13699.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Dihydrouracil Dehydrogenase (NADP)*/metabolism
Population Health*
Child ; Humans ; Haplotypes ; Antimetabolites, Antineoplastic ; Pharmacogenomic Testing ; Genotype
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia.
Autorzy:
Zheng F; Department of Hematology, Baiyun Hospital Affiliated to Guizhou Medical University, Guiyang, People's Republic of China.
Li Q; Department of Hematology, Cangzhou people' Hospital, Cangzhou, People's Republic of China.
Yang S; Department of Hematology, Baiyun Hospital Affiliated to Guizhou Medical University, Guiyang, People's Republic of China.
Zhou Z; Department of Hematology, Baiyun Hospital Affiliated to Guizhou Medical University, Guiyang, People's Republic of China.
Zeng Q; Department of Hematology, Baiyun Hospital Affiliated to Guizhou Medical University, Guiyang, People's Republic of China.
Liu K; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2276550. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myeloid, Acute*
Hematopoietic Stem Cell Transplantation*
Male ; Female ; Humans ; Young Adult ; Adult ; Middle Aged ; Aged ; Azacitidine/therapeutic use ; Thalidomide/therapeutic use ; Danazol/therapeutic use ; Antimetabolites, Antineoplastic/therapeutic use ; Retrospective Studies ; Recurrence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org.
Autorzy:
Taylor ZL; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Miller TP; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.; Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Poweleit EA; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Biomedical Informatics, University of Cincinnati, Cincinnati, Ohio, USA.; Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
DeGroote NP; Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Pommert L; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.; Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Awoniyi O; Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Board SG; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Ugboh N; Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Joshi V; Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Ambrosino N; Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Chavana A; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Bernhardt MB; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.; Texas Children's Cancer Center, Houston, Texas, USA.
Schafer ES; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.; Texas Children's Cancer Center, Houston, Texas, USA.
O'Brien MM; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.; Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Castellino SM; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.; Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Ramsey LB; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.; Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Nov; Vol. 16 (11), pp. 2130-2143. Date of Electronic Publication: 2023 Aug 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Methotrexate*
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Adolescent ; Young Adult ; Child ; Humans ; Antimetabolites, Antineoplastic/pharmacokinetics ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An Organofluorine Isoselenocyanate Analogue of Sulforaphane Affects Antimetabolite 5-Fluorouracil's Anticancer Activity: A Perspective for New Combinatory Therapy in Triple-Negative Breast Cancer.
Autorzy:
Milczarek M; Laboratory of Translation Research, Department of Biomedical Research, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.
Cierpiał T; Division of Organic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Łódź, Poland.
Kiełbasiński P; Division of Organic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Łódź, Poland.
Małecka-Giełdowska M; Department of Laboratory Medicine, Medical University of Warsaw, Stefana Banacha 1A, 02-097 Warsaw, Poland.; Central Laboratory, Central Teaching Hospital University Clinical Center, Medical University of Warsaw, Stefana Banacha 1A, 02-097 Warsaw, Poland.
Świtalska M; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114 Wrocław, Poland.
Wietrzyk J; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114 Wrocław, Poland.
Mazur M; Faculty of Chemistry, University of Warsaw, Ludwika Pasteura 1, 02-093 Warsaw, Poland.
Wiktorska K; Laboratory of Translation Research, Department of Biomedical Research, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.; Department of Physics and Biophysics, Institute of Biology, Warsaw University of Life Sciences-SGGW, Nowoursynowska 166, 02-776 Warsaw, Poland.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Aug 01; Vol. 28 (15). Date of Electronic Publication: 2023 Aug 01.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/metabolism
Mice ; Animals ; Humans ; Antimetabolites/pharmacology ; Antimetabolites/therapeutic use ; Cell Line, Tumor ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use ; Sulfoxides/pharmacology ; Immunosuppressive Agents/pharmacology ; Apoptosis ; Cell Proliferation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cost–Utility and Budget Impact Analyses of Oral Chemotherapy for Stage III Colorectal Cancer: Real-World Evidence after Policy Implementation in Thailand.
Autorzy:
Phisalprapa, Pochamana (AUTHOR)
Kositamongkol, Chayanis (AUTHOR)
Korphaisarn, Krittiya (AUTHOR)
Akewanlop, Charuwan (AUTHOR)
Srimuninnimit, Vichien (AUTHOR)
Supakankunti, Siripen (AUTHOR)
Apiraksattayakul, Natnasak (AUTHOR)
Chaiyakunapruk, Nathorn (AUTHOR)
Pokaż więcej
Źródło:
Cancers. Oct2023, Vol. 15 Issue 20, p4930. 16p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Second-line Modified GTX versus Gemcitabine- Nab-Paclitaxel (GmAb) Following First-Line FOLFIRINOX in Advanced Pancreatic Cancer: A Retrospective Analysis at the American University of Beirut Medical Center (AUBMC).
Autorzy:
Temraz, Sally
Kreidieh, Firas
Nassar, Farah
Mezher, Maria
Mukherji, Deborah
Shamseddine, Ali
Pokaż więcej
Źródło:
Middle East Journal of Cancer. Oct2023, Vol. 14 Issue 4, p550-558. 9p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 7516

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies